Break it Down: One step closer to treating ALS
Neurizon Therapeutics continues to make strides on its NUZ-001 treatment for ALS, paving the way for next stage clinical trials.
Stockhead
Don't miss out on the headlines from Stockhead. Followed categories will be added to My News.
Stockhead’s Break it Down brings you today’s leading market news in under 90 seconds.
In this episode, Tylah Tully gives the skinny on Neurizon Therapeutics (ASX:NUZ) HEALEY ALS Platform Trial, as the company makes progress developing its lead asset NUZ-001.
Tune in to get the latest.
Originally published as Break it Down: One step closer to treating ALS
TKM’s potential company maker at Christmas Creek
Championed by the original visionaries behind Pilbara Minerals and Newmont’s exploration work, Trek Metals is hoping to bring the true scale of Christmas Creek to light.
Read more
Vital signs: Optiscan
Nadine chats to Dr Camile Farah CEO and Managing Director of Optiscan (ASX:OIL) about their recently unveiled InForm device
Read more
Race initiates first site for Phase I trial
Southside Cancer Care Centre in Miranda initiated as first site for Race’s Phase I trial of cardioprotective therapy RC220 in advanced solid tumours.
Read more
ReNerve’s NervAlign gives post-op pain relief
ReNerve’s NervAlign Nerve Cuff shown to reduce post-op pain in foot and ankle peripheral nerve-repair surgeries
Read more
StockTake: Coolabah Metals
Coolabah Metals takes a 70% interest in a Broken Hill joint venture and opens a new silver-lead-zinc source for its Rasp mine.
Read more
Long Shortz: Alice Queen
Alice Queen’s drilling at Viani in Fiji has revealed encouraging gold results, setting AQX up well for the rest of the campaign.
Read more